The COVID-19 pandemic has caused more than 745 000 deaths in the US. However, the toll
might have been higher without the rapid development and delivery of effective vaccines. As …

The limited supply of vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) raises the question of targeted vaccination. Many countries have opted to …

There is growing concern that Coronavirus Disease 2019 (COVID-19) vaccine fatigue will be
a major obstacle in maintaining immunity in the general population. In this study, we …

Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the
testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 …

Vaccination constitutes the best long-term solution against Coronavirus Disease-2019;
however, vaccine-derived immunity may not protect all groups equally, and the durability of …

(COVID-19) pandemic, hopefully, will be a globally implemented, safe vaccination program
that has broad clinical and socioeconomic benefits. Dozens of vaccines are in development …

The effectiveness of a 3rd dose of SARS-CoV-2 vaccines waned quickly in the Omicron-
predominant period. In response to fast-waning immunity and the threat of Omicron variant …

In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …

INTRODUCTION Mass vaccination against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) offers the most efficient public health intervention to control the COVID-19 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections in
vaccinated individuals and reinfections in previously infected individuals have become …